Related Experiment Videos
Human immunodeficiency virus western blot tests: comparisons and considerations
A B Glassman1, T Sherrill, J Paolini
1Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston 25514.
Annals of Clinical and Laboratory Science
|September 1, 1990
Summary
Four human immunodeficiency virus (HIV) Western Blot (WB) tests were compared. Results showed variability, especially for nonreactive enzyme immunoassay (EIA) sera, highlighting the need for standardization.
Area of Science:
- Medical Diagnostics
- Virology
- Immunology
Background:
- Human immunodeficiency virus (HIV) Western Blot (WB) tests are crucial for diagnosing acquired immunodeficiency syndrome (AIDS).
- Variability in commercial HIV WB test performance can impact diagnostic accuracy.
Purpose of the Study:
- To compare the performance of four commercially available HIV Western Blot (WB) test kits.
- To evaluate the consistency and reliability of different HIV WB methods.
Main Methods:
- Tested 974 serum specimens using four distinct commercial HIV WB kits (Kits I, II, III, and IV).
- Interpreted all HIV WB results according to established criteria from the Morbidity and Mortality Weekly Report.
- Categorized specimens based on initial HIV enzyme immunoassay (EIA) results as repeatedly reactive (R) or nonreactive (NR).
Main Results:
- 65% of specimens were repeatedly reactive (R) by EIA, and 35% were nonreactive (NR).
- HIV WB results exhibited significant variability, particularly for EIA nonreactive (NR) sera, with a notable proportion falling into the indeterminate (I) category.
- Commercial HIV WB tests demonstrated differences in sensitivity and specificity.
Conclusions:
- Commercial HIV Western Blot (WB) tests show variability in performance.
- Standardization of reagents, controls, and interpretation criteria is essential for accurate HIV diagnosis.
- Further research is needed to improve the consistency of HIV WB testing.